跳至主要内容
临床试验/CTRI/2024/06/069470
CTRI/2024/06/069470尚未招募4 期

Effectiveness and safety of tadalafil in comparison with sildenafil in the group -3 pulmonary hypertension patients: A randomized, open label, parallel group study - NI

Midhun Sakravarthy J0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Patients of either gender
  • 2. Aged more than 18 years
  • 3. Patients who are diagnosed with Pulmonary Hypertension based on 2D-Echo having
  • any pulmonary etiology (Group 3) not on any pulmonary vasodilator therapy and
  • WHO Functional Class II-III

排除标准

  • 1. Impaired hepatic Function with elevated AST or ALT levels = 3 times the upper limit
  • 2. Patient with history of renal disease or impaired kidney function with elevated Serum
  • 3. Pregnant and lactating women
  • 4. Patients requiring nitrate therapy for any clinical indication.
  • 5. Contraindication to Tadalafil or Sildenafil use including allergy to any PDE-5
  • inhibitor, anatomical deformations of the penis, sickle cell anemia, multiple
  • myeloma, leukemia, bleeding disorders, active peptic ulcer disease, retinitis
  • pigmentosa or other retinal disorders
  • 6. The use or anticipated use of any of the following drugs: any nitrate, protease
  • inhibitor, anti-fungal agent and/or rifampin, or doxazosin.
  • 7. Known malignancies
  • 8. Known other heart related co-morbid

研究者

发起方
Midhun Sakravarthy J

相似试验

A study to compare the beneficial effect and safety... | 临床试验